The good thing about J.P. Morgan Week is that it draws innovative people who want to invest. The question is, should healthcare capital be focused on solving big problems and getting rewarded for them, or just focused on the status quo?
Researchers have developed a new way to attack cancer: using a non-toxic dose of sodium formate—found in nettles and ants—to trigger an organic-osmium compound.
In a new study, melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone, researchers report.
It has been widely reported that bacteria will evolve to render antibiotics mostly ineffective by mid-century—and current strategies to make up for the projected shortfalls haven’t worked.
Johnson & Johnson decided to kick start the new year by striking 15 new collaborations to drive the development of novel solutions to impact healthcare.
Alnylam Pharmaceuticals have announced a strategic restructuring of their RNAi therapeutics alliance with French pharmaceuticals company, Sanofi.
With drug development and other treatments, outcomes for the vast majority of diseases have improved over the past few decades, while life expectancy for sickle cell patients has declined.
A drug developed for type 2 diabetes has “significantly reversed memory loss” in mice with Alzheimer’s disease, and researchers now want to test it on humans.
Roughly 3% of the population have drug receptors that are so genetically different, they are more likely to have altered or adverse reactions to medicines.
An immuno-oncology drug that’s in the works could generate significant revenue growth someday.
Selectively destroying myofibroblasts that drive the fibrosis seemed to halt or even reverse fibrosis’s damaging effects in mice.
Sanofi’s Admelog is the first meal-time insulin copy the FDA has approved.